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Disclosures

Learning Objectives

1. To identify the spectrum of
peripartum mood disorders, their
features, diagnostic criteria, and
treatments.
2. To review FDA pregnancy safety
categories and lactation
categories for commonly
prescribed mood medications.
3. To identify the role of family
physicians in identifying and
treating peripartum mood
disorders.

Deﬁnitions
“Baby blues” = feelings of depression or anxiety that start soon after delivery and
generally self-resolve without intervention within 2 weeks. 6

Postpartum depression (PPD) = minor depressive symptoms or unipolar major
depressive disorder occurring during pregnancy or in the 4 weeks (academic
deﬁnition) - 12 months (used in clinical practice) after delivery. 2

Postpartum anxiety (PPA) = anxiety disorders, including OCD, present in the
perinatal period. 2

Postpartum psychosis (PPP) = disorganization, hallucinations, and/or bizarre behavior
that occurs within 4 weeks of delivery. 14

Relevance to primary care
and the role of family
medicine:

Role of Family Medicine
Approximately ⅓ of pregnant women in the U.S. have received some form of care
(prenatal or otherwise) from a family medicine physician in the past year. 5
Family medicine providers see patients in the preconception phase when they can
identify potential risk factors for perinatal mood disorders and optimize management.
Family medicine providers see infants for more frequent visits after birth, presenting
opportunities to also check in with new parents.

Epidemiology and Natural Course of the “Baby Blues”
In a systematic review and meta analysis of publications from three international
databases, authors found that the prevalence of “baby blues” was around 39%. 8
The term, “baby blues,” is frequently used to describe a constellation of symptoms
including anxiety, sadness, irritability, sleep disturbances, appetite changes, confusion
and fatigue that most commonly begins 2-5 days after delivery and persists for no more
than 2 weeks. 9
Important to note, “baby blues,” does not impair daily functioning or ability to care for
the baby and resolves without treatment. 9

Case #1: Beatrice

Case #1
Beatrice is a 24y/o G4P4 with PMH MDD (on no meds in pregnancy), gHTN who sees
you in the oﬃce 3 weeks postpartum for an infant weight check. She is accompanied
by her 3 other children, all of whom are screaming when you enter the exam room. She
expresses concern that she will not be able to ﬁgure out how to get her newborn
insurance by the time he is 1 month old. She currently has Keystone First.

What risk factors does this patient have for developing postpartum depression?

Epidemiology of Postpartum Depression
World-wide rates of PPD vary signiﬁcantly.1
●
●

High-income countries (including the U.S.): 7-13%
Low/Middle-income countries: 20%

Risk factors for developing PPD include: 2
●
●
●

History of prior mood disorder
Family history of PPD
Poor support systems
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Epidemiology of Postpartum Depression
One U.S. study estimated that 27% of PPD begins pre-pregnancy and 33% of PPD
begins during pregnancy. 3
Poor identiﬁcation and measurement of symptoms in pregnancy may lead to women
being classiﬁed as having postpartum onset of symptoms as opposed to peripartum
onset of symptoms.
Some evidence suggests that depressive symptoms may actually be more prevalent
during pregnancy than after delivery. 4

Pathophysiology: Possible Role of Reproductive Hormones in PPD
Although most risk factors for PPD are not necessarily speciﬁc to the perinatal period,
there is some evidence that suggests the existence of a subtype of PDD characterized
by sensitivity to ﬂuctuating reproductive hormone levels. 2
Rapid changes in estradiol and progesterone following delivery can trigger the onset of
symptoms in susceptible women with this phenotype. 9
Low levels of oxytocin in the third trimester are correlated with increased depressive sx
during pregnancy and after delivery. 9

Screening and Diagnosis of Postpartum Depression
DSM5 Criteria for diagnosis = a major
depressive episode with peripartum onset. 9
Five depressive symptoms (below) must be
present for at least 2 weeks:
●
●
●
●
●
●
●
●
●

Depressed mood present most of day
Loss of interest or pleasure
Insomnia or hypersomnia
Psychomotor retardation or agitation
Worthlessness or guilt
Lack of energy/fatigue
Impaired concentration/ indecisiveness
Weight or appetite change
Suicidal ideation

Treatment of Postpartum Depression
Mild-Moderate Postpartum Depression
●

Psychotherapy is ﬁrst line. 9

Moderate-Severe Postpartum Depression
●
●
●
●

Combination of psychotherapy and pharmacotherapy is ﬁrst line. 9
SSRIs, SNRIs, Mirtazapine (minimum 6-12 months)
ECT for those who fail 4 consecutive medication trials, particularly helpful in
settings of psychosis, plans for suicide/infanticide, refusal to eat.
IV Brexanalone for those who fail ECT, decline.

Medication Risks in the Peripartum Period
FDA Pregnancy Categories:

Lactation Risk Categories:

A - adequate studies have not shown risk to fetus
in the ﬁrst trimester (or beyond).

L1 - no demonstrated risk to infant in controlled
studies.

B - animal studies have shown no risk to fetus. No
data from human studies.

L2 - studied in limited number of women without
adverse eﬀects in infants.

C - adverse eﬀects in animal studies. No data from
human studies. Beneﬁts > risks.

L3 - No controlled studies in breastfeeding women.
Risk is possible.

D - evidence of fetal risk based on investigational
or marketing studies in humans. Beneﬁts may
warrant use in certain situations.

L4 - Evidence of risk in breastfed infants. Beneﬁts
may warrant use in certain situations.

X - evidence of fetal risk based on investigational
or marketing studies in humans. Risks > Beneﬁts

L5 - Signiﬁcant documented risk to infants. Risks >
Beneﬁts

Antidepressants: Safety During Pregnancy and Breastfeeding 13
Antidepressant

FDA
Pregnancy
Category

Lactation
Risk
Category

Notes

Sertraline (Zoloft)

C

L2

Considered a preferred antidepressant with
breastfeeding

Fluoxetine (Prozac)

C

L2/ L3

L2 (older infants)
L3 (neonates)

Paroxetine (Paxil)

D

L2

Significant withdrawal syndrome for infants
exposed in utero.

Citalopram (Celexa)

C

L3

Citalopram is less compatible with
breastfeeding than escitalopram.

Escitalopram (Lexapro)

C

L3

Venlafaxine (Effexor)

C

L3

Antidepressants: Safety During Pregnancy and Breastfeeding 13
Antidepressant

FDA
Pregnancy
Category

Lactation
Risk
Category

Bupropion (Wellbutrin)

B

L3

Mirtazapine (Remeron)

C

L3

Trazodone (Desyrel)

C

L2

Amitriptyline

C

L2

Nortriptyline (Pamelor)

C

L2

Duloxetine (Cymbalta)

C

-

Buspirone (Buspar)

B

L3

Case #2: Ella

Case #2
Ella is a 29y/o G1P1 who presents 6 weeks postpartum for her Liletta IUD insertion.
Her Edinburgh score is a 9. As you reach for the door knob, she mentions that she has
been feeling increasingly panicky over recent weeks. She perseverates frequently over
fears that she will drop her new baby. These used to occur only when she was at a
signiﬁcant height or near a ledge, but now these intrusive thoughts occur almost any
time she stands up holding the baby. Every time this happens, she reswaddles the baby
and readjusts her grip.

Which peripartum mood disorder might you be concerned about?

Epidemiology of Postpartum Anxiety Disorders
The prevalence of PPA has been estimated at approximately 13%, which approximates
the prevalence of anxiety disorders in the population at large. 2
There appears to be a signiﬁcantly higher rate of obsessive compulsive disorder in
pregnant and postpartum women than in non-pregnant women. 2
Risk Factors include: 12
●
●
●
●

Postpartum depression (often co-morbid)
Past history of mood disorders
Lack of social support
Low income/educational attainment

Screening and Diagnosis of Postpartum Anxiety
An EPDS may ﬂag as positive due to the coexistence of multiple perinatal mood disorders. 2
GAD-7 has not been validated for perinatal populations. 11
Other screening tools exist but do not seem to be used in the clinical setting in which we
work: 11
●

Postpartum Speciﬁc Anxiety Scale (PSAS) 10
○

●

Brief Measure of Worry Severity (BMWS)
○

●

Examines clinical and personality correlates of severe worriers

Cambridge Worry Scale (CWS)
○

●

51 questions!

16 questions related to pregnancy/birth speciﬁc situations

Pregnancy Related Anxiety Questionnaire Revised (PRAQ-R)
○

Validated only in nulliparous (not parous) women

Treatment of Postpartum Anxiety
There is a signiﬁcantly smaller body of research for perinatal mood disorders other
than postpartum depression.
Thus, most of the treatment methods for postpartum anxiety are extrapolated from the
treatment of anxiety during other periods of life.
Psychotherapy and medications such as SSRIs are mainstays of therapy. 2
Benzodiazepines are considered FDA Class D during pregnancy due to small
teratogenic risks in the ﬁrst trimester and “ﬂoppy infant syndrome” if used close to
delivery. They are considered L3 risk for breastfeeding.
●

ACOG: If beneﬁts > risks, use them! 13

Case #3: Maya

Case #3
Maya is a 44y/o G3P3003 with PMH bipolar I (stopped her meds halfway through
pregnancy), cHTN, hypothyroidism on Synthroid who sees you in clinic PPD#6 for her
infant’s weight check. She presents with her partner, who pulls you aside to conﬁde in
you that she is worried about Maya’s behavior. She reports that Maya has been having
signiﬁcant diﬃculty sleeping since bringing the infant home and yesterday became
suddenly paranoid that her partner intended to harm the baby. She has been
referencing events that her partner has no recollection of occuring.

Which peripartum mood disorder might you be concerned about?

Epidemiology of Postpartum Psychosis
The prevalence of postpartum psychosis worldwide is approximately 0.2%. 7
Filicide rates are approximately 4.5% in those experiencing postpartum psychosis. 7

Risk factors: 14
●
●
●
●

Primiparity
Advanced maternal age
History of Bipolar I disorder
History of Postpartum Psychosis

Screening and Diagnosis of Postpartum Psychosis
The Mood Disorder Questionnaire (MDQ) is a 5-item screening questionnaire for bipolar
disorder, validated for use both during and outside of the peripartum period.
Typical onset of PPP is 3-10 days after delivery, and by DSM5 criteria, must occur within 4
weeks of delivery. 14
Presenting symptoms include: 15
●
●
●
●
●
●

Insomnia
Mood ﬂuctuation
Disorganization
Bizarre behavior
Hallucinations (tactile, visual, olfactory > auditory)
Paranoid, grandiose delusions

Treatment of Postpartum Psychosis
Postpartum psychosis is a psychiatric emergency, and therefore an indication for
hospitalization.
Women with a history of postpartum psychosis should begin lithium therapy
immediately after delivery as prophylaxis. 14
Benzodiazepines are used for symptoms of insomnia and agitation in the treatment of
PPP. 15
Atypical antipsychotics (Latuda, Abilify) and mood stabilizers can be used for
psychotic and manic symptoms in the treatment of PPP. 14
Maintenance treatment with lithium monotherapy is recommended for at least 9
months postpartum to decrease risk of relapse. 15

Resources in Philadelphia:

Resources in Philadelphia
Maternity Care Coalition MoMobile
Family Therapy Program:
●

●

behavioral health services for
low-income pregnant women and
mothers with young children (ages 0
to 3).
identiﬁes and treats issues of perinatal
depression and/or other behavioral
health conditions such as PTSD,
anxiety disorders, and co-occurring
substance dependence.

Take Home Points

1. There is a wide spectrum of
peripartum mood disorders, not just
postpartum depression!
2. Mainstays of therapy for both
postpartum anxiety and depression
include psychotherapy and SSRIs.
3. Postpartum psychosis is a psychiatric
emergency warranting inpatient,
multidisciplinary treatment.
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